Inventor · disambiguated record
Douglas Dong Fang
Also filed as: FANG DOUGLAS · FANG DOUGLAS D · FANG DOUGLAS DONG
13 granted patents·17 pending applications·7 citations·filing 2006–2025
83Inventor score
Top patents by PatentIndex Score
30 records- 0190US11452716B2Pharmaceutical composition and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Sep 27, 2022·3 cites·20 claims
- 0283US11478469B2Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseasesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Oct 25, 2022·2 cites·10 claims
- 0378US12268665B2Combination of immunotherapies with MDM2 inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Apr 8, 2025·1 cites·13 claims
- 0478US11395815B2Compound for treating osteoarthritisASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Jul 26, 2022·1 cites·14 claims
- 0572US2024390401A1Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2024·Application pending·0 cites
- 0667US12083136B2Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Sep 10, 2024·0 cites·4 claims
- 0763US12370197B2Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseasesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Jul 29, 2025·0 cites·8 claims
- 0863US12233047B2Pharmaceutical combination and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Feb 25, 2025·0 cites·20 claims
- 0963US2025152580A1Methods for treating immune diseasesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 1062US2025361240A1Pyranopyridine compound, process for preparing the same, pharmaceutical composition and use thereofZHEJIANG YANGLI PHARMACEUTICAL TECH CO LTD·Filed 2025·Application pending·0 cites
- 1159US2025099440A1A pharmaceutical combination and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1257US2025235426A1Pharmaceutical Combination and Use ThereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2025·Application pending·0 cites
- 1357US2024316051A1A pharmaceutical combination and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1457US2024366611A1Methods of treating a disease or disorderASCENTAGE PHARMA SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1556US2024316069A1Methods of treating multiple sclerosisASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 1656US2023381176A1A pharmaceutical composition and use thereof for treatment of cancerASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 1756US2023398110A1Compositions and methods for treating non-alcoholic steatohepatitisASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 1854US12287338B2Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathwayASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Apr 29, 2025·0 cites·12 claims
- 1954US2023078120A1Methods for Treating Coronavirus InfectionsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 2053US2021275522A1Pharmaceutical compositions and use thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Application pending·0 cites
- 2152US12194024B2Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating diseaseASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Granted Jan 14, 2025·0 cites·5 claims
- 2252US12186304B2Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint moleculeASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Jan 7, 2025·0 cites·22 claims
- 2352US11478477B2Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitorASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Oct 25, 2022·0 cites·18 claims
- 2452US2023029259A1Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agentsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 2552US2023218575A1Microsuspension of an mdm2 inhibitor and therapeautic applications thereofASCENTAGE PHARMA SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 2649US11478470B2Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseasesASCENTAGE PHARMA SUZHOU CO LTD·Filed 2019·Granted Oct 25, 2022·0 cites·11 claims
- 2749US2022233558A1Method and composition for predicting efficacy of bcl2/bcl-xl inhibitors on cancerASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 2847US2021311020A1Treatment methods and biomarkers for mdm2 inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 2947US2025195473A1Combination of immunotherapies with mdm2 inhibitorsASCENTAGE PHARMA SUZHOU CO LTD·Filed 2025·Application pending·0 cites
- 3040US8999706B2Methods for preparation of human hair-follicle derived multipotent adult stem cellsXU XIAOWEI·Filed 2006·Granted Apr 7, 2015·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Douglas Dong Fang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →